default author photo

Nozomi Shiwa

National Institute of Infectious Diseases - Department of Pathology

Japan

SCHOLARLY PAPERS

3

DOWNLOADS

112

TOTAL CITATIONS

1

Scholarly Papers (3)

1.

Broad Neutralization Activity of SARS-CoV-2 Antibody is Achieved by Coordinated Recognition of Virus Vulnerable Site

Number of pages: 52 Posted: 01 Apr 2021
National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Hokkaido University - Laboratory of Biomolecular Science, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Hokkaido University - Division of Molecular Pathobiology, Hokkaido University - Center for Research and Education on Drug Discovery, Osaka University - Laboratory of Lymphocyte Differentiation, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Division of Molecular Pathobiology, Hokkaido University - Division of Molecular Pathobiology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, Kyushu University - Department of Virology, Kyushu University - Department of Virology, National Institute of Infectious Diseases - Pathogen Genomic Center, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Department of Virology I, Tottori University - Chromosome Engineering Research Center, Tottori University - Chromosome Engineering Research Center, National Institute of Infectious Diseases - Department of Immunology, Trans Chromosomics Inc., Osaka University - Laboratory of Lymphocyte Differentiation, National Institute of Infectious Diseases - Pathogen Genomic Center, National Institute of Infectious Diseases - Department of Pathology, Hokkaido University - Division of Molecular Pathobiology, Kyushu University - Department of Virology, Hokkaido University - Laboratory of Biomolecular Science and National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development
Downloads 49 (1,074,648)

Abstract:

Loading...

2.

Neutralizing Antibody-Independent SARS-CoV-2 Control Correlated with Intranasal Vaccine-Induced CD8 + T-Cell Responses

Number of pages: 40 Posted: 15 Sep 2021
National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Veterinary Science, National Institute of Infectious Diseases - Department of Veterinary Science, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, ID Pharma Co., Ltd., ID Pharma Co., Ltd., National Institute of Infectious Diseases - Management Department of Biosafety and Laboratory Animal, National Institute of Infectious Diseases - Management Department of Biosafety and Laboratory Animal and National Institute of Infectious Diseases - AIDS Research Center
Downloads 36 (1,236,159)
Citation 1

Abstract:

Loading...

COVID-19, vaccine, CD8+ T cell, viral vector, variant

3.

Intranasal Vaccination Induced Cross-Protective Secretory IgA Antibodies Against SARS-CoV-2 Variants with Reducing the Potential Risk of Lung Eosinophilic Immunopathology

Number of pages: 48 Posted: 16 Jun 2022
National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, Kyoto University, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, Tokyo University of Science - Department of Biological Science and Technology, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases and National Institute of Infectious Diseases
Downloads 27 (1,359,097)

Abstract:

Loading...

intranasal vaccination, secretory IgA antibody, COVID-19, SARS-CoV-2, lung eosinophilic immunopathology